Share 'A New Model for Drug Development in Rare Disease: Gaining Approval as a Class'
The CEO of AVI Biopharma is speaking in Geneva tomorrow and the topic of the presentation is very interesting to me, as a father of a boy who is not in the "hot-zone" for current exon-skipping clinical trials.
Gaining approval of AVI or Prosensa treatments as a class is the only way those drugs can help my son in time.
Is anybody at PPMD going attending this conference? If so, can you publish the…
You can share this discussion in two ways…
Share this link:
Send it with your computer's email program: Email this